Alyeska Investment Group’s Pfizer PFE Stock Holding History

Alyeska Investment Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-313,460	Closed	-$9.26M	–	561
2014 Q4	$9.26M	Buy	+313,460	New	+$8.99M	0.16%	214

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Alyeska Investment Group's PFE Position: Q3 2024 in Review

Alyeska Investment Group sold out of Pfizer (PFE) in Q3 2024, closing a stake of 2,000,000 shares — an estimated $56M sold.

Alyeska Investment Group first reported a position in PFE in Q2 2013 and held it in 10 quarters. The position peaked at $80.7M in Q3 2015. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

Alyeska Investment Group reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
Alyeska Investment Group sold 2,000,000 Pfizer shares in Q3 2024, an estimated $56M.
Alyeska Investment Group first reported a position in Pfizer in Q2 2013 and held it in 10 quarters.
Alyeska Investment Group's Pfizer position peaked at $80.7M in Q3 2015.
2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.